Robbins Arroyo LLP: Synergy Pharmaceuticals Inc. (SGYP) Misled Shareholders According to a Recently Filed Class Action

SAN DIEGO & NEW YORK--()--Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Synergy Pharmaceuticals Inc. (NasdaqGS: SGYP) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between September 5, 2017 and November 14, 2017. Synergy, a biopharmaceutical company, develops and commercializes novel therapies to treat gastrointestinal diseases and disorders

View this information on the law firm's Shareholder Rights Blog:
www.robbinsarroyo.com/synergy-pharmaceuticals-inc

Synergy Accused of Taking Out Large Loan at Shareholders' Expense

According to the complaint, on September 5, 2017, Synergy announced that it closed on a $300 million senior secured loan from CRG Partners III L.P. Synergy said the loan was non-dilutive and would give the company the ability to launch its drug, Trulance, and achieve its business objectives, which it was confident would maximize long-term shareholder value and fund the company's plans through 2019. Consequently, investors were under the impression that Synergy would successfully develop and profit from Trulance without needing to raise additional capital or dilute stockholders' outstanding equity interests. The CRG loan, however, had critical undisclosed terms and conditions that prevented Synergy from accessing funds "when needed." As a result, in order to fund its operations, on November 14, 2017, Synergy conducted a secondary offering of approximately 22 million shares for net proceeds of $52.4 million. The 10% dilutive capital increase was described by investors as "unexpected," "blindsiding," and stoked "fears about further unexpected dilution."

Synergy Shareholders Have Legal Options

If you would like more information about your rights and potential remedies, contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Robbins Arroyo LLP
Leonid Kandinov
(619) 525-3990 or Toll Free (800) 350-6003
LKandinov@robbinsarroyo.com
www.robbinsarroyo.com

Release Summary

Do you own shares of Synergy Pharmaceuticals Inc.? Robbins Arroyo LLP is investigating claims on behalf of shareholders of Synergy.

$Cashtags

Contacts

Robbins Arroyo LLP
Leonid Kandinov
(619) 525-3990 or Toll Free (800) 350-6003
LKandinov@robbinsarroyo.com
www.robbinsarroyo.com